Showing 1 - 12 of 12 trials – Showing only trials currently accepting patients

• CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma

  Stanford is currently accepting patients for this trial.

• Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

  Stanford is currently accepting patients for this trial.

• Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease

  Stanford is currently accepting patients for this trial.

• DALY 2.0 USA/ MB-CART2019.1 for DLBCL

  Stanford is currently accepting patients for this trial.

• CTL019 Out of Specification MAP for ALL or DLBCL Patients

  Stanford is currently accepting patients for this trial.

• Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol

  Stanford is currently accepting patients for this trial.

• Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma

  Stanford is currently accepting patients for this trial.

• CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies

  Stanford is currently accepting patients for this trial.

• Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma (ALPHA2)

  Stanford is currently accepting patients for this trial.

• A Safety and Efficacy Study of ADI-001, an Anti-CD20 Allogeneic Gamma Delta CAR-T, in Subjects With B Cell Malignancies

  Stanford is currently accepting patients for this trial.

• A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)

  Stanford is currently accepting patients for this trial.

• A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors

  Stanford is currently accepting patients for this trial.